Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.
| Drug | Target | Relationship | GBM | LUAD | SCLC | LUSC | OAC | OSCC | PDAC | Reposition | #cancers |
|---|---|---|---|---|---|---|---|---|---|---|---|
| intestinal, multivisceral or modified multivisceral transplantation, alemtuzumab, tacrolimus, sirolimus | FKBP1A | Direct | 1 | ||||||||
| mycophenolate mofetil, tacrolimus, post-transplant cyclophosphamide, total body irradiation, hematopoietic cell transplant, jsp191, cyclophosphamide, fludarabine | FKBP1A | Direct | 1 | ||||||||
| pacritinib, sirolimus, tacrolimus, allogenic hematopoietic cell transplant (allohct) | FKBP1A | Direct | 1 | ||||||||
| tacrolimus modified release (mr), tacrolimus | FKBP1A | Direct | 1 | ||||||||
| tacrolimus, methotrexate, sirolimus | FKBP1A | Direct | 1 | ||||||||
| tacrolimus, tacrolimus immediate release | FKBP1A | Direct | 1 | ||||||||
| treosulfan, fludarabine phosphate, tacrolimus, methotrexate, lapine t-lymphocyte immune globulin, peripheral blood stem cell transplantation, allogeneic bone marrow transplantation, quality-of-life assessment, echocardiography, multigated acquisition scan, bone marrow biopsy, bone marrow aspiration, biospecimen collection, x-ray imaging, computed tomography | FKBP1A | Direct | 1 | ||||||||
| everolimus | FKBP1A | Direct | yes | 0 | |||||||
| pimecrolimus | FKBP1A | Direct | yes | 0 | |||||||
| rapamycin | FKBP1A | Direct | yes | 0 | |||||||
| tacrolimus | FKBP1A | Direct | yes | 0 | |||||||
| temsirolimus | FKBP1A | Direct | yes | 0 | |||||||
| adagrasib | KRAS | SSL via KRAS | yes | 2 | |||||||
| sotorasib | KRAS | SSL via KRAS | yes | 2 | |||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | MAP2K1 | SSL via MAP2K1 | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | YES1 | SSL via YES1 | 2 | ||||||||
| alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel | MAP2K1 | SSL via MAP2K1 | 2 | ||||||||
| binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib | MAP2K1 | SSL via MAP2K1 | 2 | ||||||||
| cft1946, trametinib, cetuximab | MAP2K1 | SSL via MAP2K1 | 2 | ||||||||
| cobimetinib, mehd7945a | MAP2K1 | SSL via MAP2K1 | 2 | ||||||||
| jab-3312, binimetinib, pembrolizumab, sotorasib, osimertinib | MAP2K1 | SSL via MAP2K1 | 2 | ||||||||
| mirdametinib, bgb-3245 | MAP2K1 | SSL via MAP2K1 | 2 | ||||||||
| nivolumab, ipilimumab, cobimetinib | MAP2K1 | SSL via MAP2K1 | 2 | ||||||||
| selumetinib, medi4736, tremelimumab | MAP2K1 | SSL via MAP2K1 | 2 | ||||||||
| 5-fluorouracil (5-fu), leucovorin, oxaliplatin, atezolizumab, cobimetinib, ramucirumab, paclitaxel, pegylated recombinant human hyaluronidase (pegph20), bl-8040, linagliptin, atezolizumab, cobimetinib, cisplatin, tiragolumab, 5-fluorouracil (5-fu) | MAP2K1 | SSL via MAP2K1 | 1 | ||||||||
| afatinib, dasatinib, palbociclib, everolimus, olaparib | YES1 | SSL via YES1 | 1 | ||||||||
| akt inhibitor mk2206, fluorouracil, oxaliplatin, selumetinib | MAP2K1 | SSL via MAP2K1 | 1 | ||||||||
| bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment | YES1 | SSL via YES1 | 1 | ||||||||
| bevacizumab, dasatinib, placebo | YES1 | SSL via YES1 | 1 | ||||||||
| binimetinib | MAP2K1 | SSL via MAP2K1 | yes | 1 | |||||||
| binimetinib, hydroxychloroquine | MAP2K1 | SSL via MAP2K1 | 1 | ||||||||
| biopsy, calaspargase pegol-mknl, cobimetinib | MAP2K1 | SSL via MAP2K1 | 1 | ||||||||
| bosutinib | MAP2K1 | SSL via MAP2K1 | 1 | ||||||||
| cobimetinib, hydroxychloroquine, atezolizumab | MAP2K1 | SSL via MAP2K1 | 1 | ||||||||
| cobimetinib, olaparib, onvansertib, azenosertib, saruparib, tremelimumab | MAP2K1 | SSL via MAP2K1 | 1 | ||||||||
| dabrafenib, trametinib | MAP2K1 | SSL via MAP2K1 | 1 | ||||||||
| dabrafenib, trametinib, carboplatin, vincristine | MAP2K1 | SSL via MAP2K1 | 1 | ||||||||
| dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride | YES1 | SSL via YES1 | 1 | ||||||||
| dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method | YES1 | SSL via YES1 | 1 | ||||||||
| dasatinib, laboratory biomarker analysis, physiologic testing | YES1 | SSL via YES1 | 1 | ||||||||
| dasatinib, mfolfox6 | YES1 | SSL via YES1 | 1 | ||||||||
| dasatinib, pharmacological study | YES1 | SSL via YES1 | 1 | ||||||||
| dasatinib, temozolomide, placebo, radiation therapy | YES1 | SSL via YES1 | 1 | ||||||||
| disulfiram, copper, alkylating agents | CALR | SSL via CALR | 1 | ||||||||
| disulfiram, copper, alkylating agents | HSPD1 | SSL via HSPD1 | 1 | ||||||||
| disulfiram, copper, alkylating agents | PRDX1 | SSL via PRDX1 | 1 | ||||||||
| enzastaurin, bevacizumab, enzyme-inducing antiepileptic drugs (eiaed), non-enzyme inducing antiepileptic drugs (neiaed) | PIK3R1 | SSL via PIK3R1 | 1 | ||||||||
| enzastaurin, lomustine | PIK3R1 | SSL via PIK3R1 | 1 | ||||||||
| enzastaurin, temozolomide, radiation therapy | PIK3R1 | SSL via PIK3R1 | 1 | ||||||||
| erlotinib hydrochloride, selumetinib, laboratory biomarker analysis | MAP2K1 | SSL via MAP2K1 | 1 | ||||||||
| gemcitabine, ribociclib, sonidegib, trametinib, filgrastim | MAP2K1 | SSL via MAP2K1 | 1 | ||||||||
| gsk2256098, trametinib | MAP2K1 | SSL via MAP2K1 | 1 | ||||||||
| mebendazole | TUBA1A | SSL via TUBA1A | 1 | ||||||||
| mebendazole, vincristine, carboplatin, temozolomide, bevacizumab, irinotecan | TUBA1A | SSL via TUBA1A | 1 | ||||||||
| mirdametinib | MAP2K1 | SSL via MAP2K1 | 1 | ||||||||
| nab-paclitaxel, gemcitabine, oxaliplatin, leucovorin, fluorouracil, atezolizumab, cobimetinib, pegph20, bl-8040, selicrelumab, bevacizumab, ro6874281, ab928, tiragolumab, tocilizumab | MAP2K1 | SSL via MAP2K1 | 1 | ||||||||
| omeprazole, melatonin | CALR | SSL via CALR | 1 | ||||||||
| patupilone | TUBA1A | SSL via TUBA1A | 1 | ||||||||
| pimasertib, gemcitabine, placebo | MAP2K1 | SSL via MAP2K1 | 1 | ||||||||
| recombinant interferon alfa-2b, cisplatin, sodium stibogluconate, dacarbazine, vinblastine | TUBA1A | SSL via TUBA1A | 1 | ||||||||
| rmc-4630, cobimetinib, drug: osimertinib | MAP2K1 | SSL via MAP2K1 | 1 | ||||||||
| selumetinib | MAP2K1 | SSL via MAP2K1 | yes | 1 | |||||||
| tovorafenib, pimasertib | MAP2K1 | SSL via MAP2K1 | 1 | ||||||||
| trametinib, erlotinib | MAP2K1 | SSL via MAP2K1 | 1 | ||||||||
| trametinib, ruxolitinib | MAP2K1 | SSL via MAP2K1 | 1 | ||||||||
| trametinib, ruxolitinib, retifanlimab | MAP2K1 | SSL via MAP2K1 | 1 | ||||||||
| trametinib, vinblastine | MAP2K1 | SSL via MAP2K1 | 1 | ||||||||
| trametinib, vinblastine | TUBA1A | SSL via TUBA1A | 1 | ||||||||
| belantamab mafodotin | TUBA1A | SSL via TUBA1A | yes | 0 | |||||||
| cobimetinib | MAP2K1 | SSL via MAP2K1 | yes | 0 | |||||||
| cobimetinib fumarate | MAP2K1 | SSL via MAP2K1 | yes | 0 | |||||||
| dasatinib | YES1 | SSL via YES1 | yes | 0 | |||||||
| docetaxel | TUBA1A | SSL via TUBA1A | yes | 0 | |||||||
| eribulin | TUBA1A | SSL via TUBA1A | yes | 0 | |||||||
| eribulin mesylate | TUBA1A | SSL via TUBA1A | yes | 0 | |||||||
| midostaurin | PRKCI | SSL via PRKCI | yes | 0 | |||||||
| selumetinib sulfate | MAP2K1 | SSL via MAP2K1 | yes | 0 | |||||||
| trametinib | MAP2K1 | SSL via MAP2K1 | yes | 0 | |||||||
| trametinib dimethyl sulfoxide | MAP2K1 | SSL via MAP2K1 | yes | 0 | |||||||
| vandetanib | YES1 | SSL via YES1 | yes | 0 | |||||||
| vinblastine | TUBA1A | SSL via TUBA1A | yes | 0 | |||||||
| vinblastine sulfate | TUBA1A | SSL via TUBA1A | yes | 0 | |||||||
| vincristine | TUBA1A | SSL via TUBA1A | yes | 0 | |||||||
| vincristine sulfate | TUBA1A | SSL via TUBA1A | yes | 0 | |||||||
| vindesine | TUBA1A | SSL via TUBA1A | yes | 0 | |||||||
| vindesine sulfate | TUBA1A | SSL via TUBA1A | yes | 0 | |||||||
| vinflunine | TUBA1A | SSL via TUBA1A | yes | 0 | |||||||
| vinorelbine | TUBA1A | SSL via TUBA1A | yes | 0 | |||||||
| vinorelbine tartrate | TUBA1A | SSL via TUBA1A | yes | 0 |